Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 59.00 13,158 08:05:36
Bid Price Offer Price High Price Low Price Open Price
59.00 61.00 61.00 59.00 61.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.92 5.52 0.81 72.8 268
Last Trade Time Trade Type Trade Size Trade Price Currency
08:05:36 AT 1,098 59.00 GBX

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:05:3659.001,098647.82AT
07:05:1159.704,7902,859.63O
07:04:2159.201,098650.02O
07:03:1559.215,0743,004.16O
07:00:0861.001,098669.78UT
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

DateSubject
28/9/2020
09:20
Ekf Diagnostics Daily Update: Ekf Diagnostics Holdings Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 59p.
Ekf Diagnostics Holdings Plc has a 4 week average price of 51.50p and a 12 week average price of 43p.
The 1 year high share price is 61p while the 1 year low share price is currently 16.93p.
There are currently 454,593,227 shares in issue and the average daily traded volume is 939,813 shares. The market capitalisation of Ekf Diagnostics Holdings Plc is £268,210,003.93.
12/9/2020
12:26
brucie5: Wan has shown an incredible capacity for detail and persistence, so if this doesn't go up considerably next week, we will all know who to blame. ;) Given HMG rhetoric over the so called 'moonshot', I'd be surprised it any mention of EKF's possible involvement would not lead to a jump in the share price. Chartwise, we're in oxymoronic territory: viz., uncharted. But with any pronounced move, we may well begin to feel the gravitational attraction of the first £. Would be nice, even if I'm not yet sure how it might be justified. Over to Wan.
20/8/2020
14:27
bones: Sounds like about 3.1p per EKF share is represented by the RENX holding still held by EKF itself. The rest of the RENX value mentioned by N+1 is the actual RENX shares distributed to the shareholders of EKF on spin-out so no longer represented in the EKF share price today. Interesting to note that RENX has a bigger market cap than EKF these days.
20/8/2020
13:55
crazycoops: So, I contacted the N+1 Singer analyst about the apparent typo and this is the clarification I received, "No, 27.9p is correct. This is made up of the 20.965m RENX shares distributed to EKF in specie + the 2.678m shares currently held on the Balance Sheet x 535p / 454.1m EKF shares in issue = 27.9p / EKF share"I am happy to put the record straight and will now go back to lurking.
15/8/2020
13:04
epicsurf: Have added again on Friday,the reaction In the share price following the 3 million initial contract win and ekf statement on revising guidance upwards again gives me confidence that further orders will happen before year end and hopefully will have the same share reaction
16/7/2020
11:14
dibs61: I’m finding the share price movements - quoted bid and offer against the trades printed - pretty odd tbh. It’s on SETS but most trades are ordinary. Is the share price action normally like this? Just a strange reaction against what was an outstanding update.
14/7/2020
09:56
wan: I don't comment much on actual share price or buying opportunities etc, preferring others to make up their own mind based on reasonable evidence/research etc. But I do think that there is (and has been for some time) an overhang of stock that's keeping the share price in check and possibly creating opportunity. It's only my perception so I could be wrong, how long it will last I have no idea, but if I am right, then there is possibly further upside over and above that indicated by EKF's continued excellent performance and positive outlook. Please conduct your own research when making investment decisions, as the originator, or any of the threads contributors, including me, could be either wrong or inaccurate.
21/7/2019
11:21
wan: The initiation of a dividend would imply that EKF are seeing a strong trend in terms of profitable growth and cash generation. And it could therefore represent a signal that EKF are entering a new phase in terms of profitable growth and hopefully share price performance. Whilst the dividend payment is subject to shareholder approval in H1 2020, the dividend yield potential (based on today's share price) is quite reasonable at circa 3% and obviously potentially greater if this proves to be an interim dividend! Importantly, the dividend is not coming at the expense for the potential of further growth. The healthy cash and marketable securities position of £15m at the half-year (giving cash and marketable securities at current market value of over £20m) would imply that the dividend payout at circa £4.5m is likely to represent a relatively low payout ratio, meaning a healthy percentage of earnings will be retained for investing and growing the business. If realised and sustained, a combination of growth, share buybacks and dividends would certainly provide for healthy and reassuring combination! EKF's revenues are generated from the point of care (POC), central laboratory and life science divisions, with the largest contribution currently coming from POC. EKF have a large installed base of POC instruments which is growing and generates reliable recurring revenues. This impressive installed base of instruments is set for improved growth and provides for stable and predictable revenues, which adds good support to providing an on-going dividend policy. The Central Laboratory provides steady and reliable revenues, and with the significant investment and upgrade to the life Science enzyme facility enabling the Oragenics, Inc contract and also providing increased capacity to accommodate additional contracts, this division should start showing very good rates of growth. An investment in EKF provides good exposure to the central laboratory/life science and POC markets. The POC market is offering a combination of growth due to wider adoption, technological advancements and favourable demographic factors, as well as providing reliable revenues and relatively high barriers to entry, and thus offers defensive qualities as POC products associated with the effective diagnosis and management of medical conditions and disease are becoming evermore essential tools. The Central Laboratory division is providing an equally reliable income stream, but due to recent investments and expansion, this division has entered a new phase that has already started delivering good rates of growth. EKF have announced that it has entered into a non-exclusive Preferred Partner Arrangement (the “Agreement”) with Mount Sinai Innovation Partners (“MSIP”) - hTTp://ip.mountsinai.org/ In connection with the Agreement, the Company has signed a non-binding term sheet with Mount Sinai, which will allow the Company to explore the opportunity to support the licensing of technology originating from Mount Sinai to establish a novel digital health platform for earlier intervention in and better management of patients with Inflammatory Bowel Disease (“IBD”). EKF website - hTTps://www.ekfdiagnostics.com/ Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate.
07/6/2019
14:29
wan: Given the continued success being reflected in share price of Renalytix, has anyone else considered the fact that the £6.4m gain recognised on EKF's books, for the year ending 2018, for the spinout of Renalytix was discounted to take account of various factors including the restrictions on the shares which were distributed to EKF’s shareholders prior to the flotation? From the Annual Report - 29. Renalytix AI plc During 2018, the Group founded Renalytix AI plc which, along with its subsidiary company Renalytix AI Inc., were floated separately from the Group in November 2018. The investment in Renalytix was previously held as an asset available for sale. Renalytix is a developer of artificial intelligence-enabled diagnostics for kidney disease. As part of the creation of a separate business, intangible assets with a net value of £646,000 were sold to Renalytix by the Group, and the Group’s wholly owned subsidiary Renalytix AI Inc. was sold to Renalytix AI plc, in return for shares in Renalytix AI plc. Following these transactions, EKF’s shareholding in Renalytix comprised 20,964,295 ordinary shares. The EKF holding was then distributed in specie to Relevant EKF shareholders, being those on the EKF register as at the date of record for the distribution in October 2018 at a rate of one Renalytix AI plc ordinary share (a “RENX share”) for each 21.825 EKF ordinary shares held. The fair value of the shares distributed to Relevant EKF shareholders was calculated based on the proposed flotation price, less a discount to account for the restrictions placed on the shares. The discount was calculated taking into account, amongst other factors, the 180 day lock up period, sector volatility, and that the shares were issued pre-admission. The total fair value of the distributed shares was calculated as £7,027,000 with the profit on disposal, which has been shown as an exceptional profit, being calculated net of expenses of £25,000 and the value of the intangible asset transferred of £6,356,000. Subsequent to the distribution, EKF invested £3.1m in the shares of Renalytix at the same price as other new investors and, as at the date of this announcement, holds 2,577,907 RENX shares. (END) That appears to indicate that the Renalytix shares were discounted back to circa 33.5p, so again it appears to indicate that there is potentially another very healthy exceptional gain to be realised. Not to mention that EKF, having purchased further shares in Renalytix, now own over 2.6 million shares at an average price of 123p.
23/10/2018
15:34
wan: Macarona...As discussed on here previously, the current EKF share price appears to have already reflected the distribution, presumably because the announcements had effectively flagged when and by how much, but as I said this morning, time will tell None of us can predict what will happen when Renalytix commences trading, but having done quite a bit of research I am quite hopeful about the near to medium term prospects for Renalytix (including potential news flow), and maybe there will be good demand for the shares (other AI in healthcare companies are certainly attaining very high valuations). So my decision to buy more EKF shares was based on the current share price pullback and the near term prospects and potential news flow for EKF, and also about getting the maximum exposure to Renalytix ahead of any high demand and potentially being scaled back on the Restricted Offer, via which I intend to also add (and possibly when trading commences too). Best wishes to all EKF and Renalytix shareholders.
20/10/2018
08:32
wan: Cambridgedon...As I said previously, there is a lot to digest! I assume we will know early next week regarding the de minimis threshold, but one assumes that what ever that threshold is, it will then be based on a round number. There are 457,554,636 shares in issue, which in your scenario would be closer to 45 or 46 shares per 1000 EKF shares. As Ingroid suggests, the current EKF share price does appear to reflect the distribution (as per the case when a stock goes ex dividend), but you will have to wait six months to ultimately realise it (if you wanted to sell). Personally speaking, I was not looking to immediately sell the Renalytix shares anyway (as I had good reasons to think that the investment prospect would be a good one), so I am not fazed by the lock-up period. I note Renalytix will also pay back all the EKF loans, so there is some cash to come back too. Overall, I am very impressed with the know-how and expertise behind Renalytix, including how they have assessed the proposition and positioned Renalytix to address the market, which is indeed very large (as are the resulting savings and resultant business proposition). EKF clearly see a good investment proposition too, as they intend to take part in the fund raise and have a notifiable interest in Renalytix. Renalytix aside, I still think that EKF is an excellent long term investment.
Ekf Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200929 07:34:21